<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226707</url>
  </required_header>
  <id_info>
    <org_study_id>CASM981M2301</org_study_id>
    <nct_id>NCT00226707</nct_id>
  </id_info>
  <brief_title>Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis</brief_title>
  <official_title>A 6-Week Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study to Investigate the Efficacy and Safety of Pimecrolimus Cream 1% in Patients With Mild-to-Moderate Chronic Hand Dermatitis Followed by a 6-Week Open-Label Phase to Assess the Safety of Pimecrolimus Cream 1%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is
      associated with adverse effects. This study will assess the efficacy and safety of
      pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">March 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigators Global Assessment (IGA) of the target hand at day 43 or at time of early discontinuation.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>IGA of the non-target hand</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itching/burning assessment for the target and non-target hand</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-key signs of hand dermatitis (vesiculation, oozing/crusts, edema/population, lichenification) at each study visit</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work productivity and activity impairment questionnaire</measure>
  </secondary_outcome>
  <enrollment>652</enrollment>
  <condition>Chronic Hand Dermatitis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pimecrolimus Cream 1%</intervention_name>
    <other_name>Elidel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Patients who are outpatients at baseline (Day 1)

          -  Patients must be 18 years of age or above

          -  Patients must have chronic hand dermatitis based upon clinical diagnosis with mild to
             moderate dermatitis of the target hand at baseline, as defined by an Investigator's
             Global Assessment score of 2 (mild) or 3 (moderate).

          -  Patients must have been informed of the study procedures and medication and have given
             their written informed consent

        Exclusion Criteria:

          -  - Women who are pregnant or who are breast-feeding.

          -  Patients who have received systemic corticosteroids (i.e., oral, intravenous,
             intra-articular, rectal, intramuscular) within one month prior to first application of
             study medication.

          -  Patients who have received phototherapy (e.g., UVB, PUVA) or systemic therapy (e.g.,
             immunosuppressants, cytostatics) known or suspected to have an effect on hand
             dermatitis within at least one month prior to first application of study medication.

          -  Patients who have received pimecrolimus cream 1% or tacrolimus ointment 0.1% or 0.03%
             within 14 days prior to first application of study medication.

          -  Patients who were treated with topical therapy (e.g., tar, topical corticosteroids,
             Burrows solution soaks) known or suspected to have an effect on hand dermatitis within
             7 days prior to first application of trial medication.

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals Japan</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2005</study_first_submitted>
  <study_first_submitted_qc>September 26, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <last_update_submitted>February 13, 2008</last_update_submitted>
  <last_update_submitted_qc>February 13, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>Chronic hand dermatitis, pimecrolimus, dermatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

